Elan Drug Technologies

18.03.10

Elan Drug Technologies Announces Pivotal Phase 3 Trial for Hydrocodone Controlled Release Fomulation by its Licensing Partner Zogenix Inc

DUBLIN, IRELAND, March 18, 2010, Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) today announced that Zogenix Inc, its licensing partner, has initiated a pivotal Phase 3 clinical trial with ZX002, a novel, oral, controlled-release formulation of hydrocodone without ...

• » Read on

01.03.10

Elan Drug Technologies Welcomes the Launch of MS Drug AMPYRA™ (Dalfampridine) Extended Release Tablets

AMPYRA™ Uses Elan’s Proprietary MXDAS™ (Matrix Drug Absorption System) Drug Delivery Technology

• » Read on

25.01.10

Elan Drug Technologies Welcomes the NDA Approval of MS Drug AMPYRA™ (Dalfampridine) Extended Release Tablets

AMPYRA™ Approved Using Elan’s Proprietary MXDAS™ (Matrix Drug Absorption System) Drug Delivery Technology

• » Read on

18.12.09

ELAN DRUG TECHNOLOGIES CELEBRATES 40 YEARS OF DRUG DELIVERY LEADERSHIP

DUBLIN, IRELAND, December 18th, 2009, Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) celebrates today its official anniversary and forty-years of leadership in the drug delivery business.   Since its founding in Ireland in 1969, Elan’s drug delivery ...

• » Read on

14.12.09

Elan Drug Technologies Announces First Japanese Approval of Product Using Its NanoCrystal® Technology.

DUBLIN, IRELAND, DECEMBER 14 2009, Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) announces the approval by the Japanese Ministry of Health, Labour and Welfare of EMEND® (aprepitant) for the treatment of cancer chemotherapy-induced nausea and vomiting.  ...

• » Read on

04.12.09

Elan Drug Technologies Announces Submission of MAA in Europe for Paliperidone Palmitate using NanoCrystal® tech

DUBLIN, IRELAND – December 4, 2009— Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) announced that Janssen-Cilag has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency for paliperidone palmitate for the treatment of ...

• » Read on

03.08.09

Elan Drug Technologies announces first approval of a long acting injectable formulation using NanoCrystal® Technology

Fifth product approved by the US FDA licensing Elan’s NanoCrystal® technology for various

• » Read on

30.06.09

Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S.

Acorda to Continue to Develop and Commercialize Fampridine-SR in the U.S. Upfront Payment

• » Read on

06.05.09

Acorda Therapeutics Announces FDA Acceptance of Fampridine-SR New Drug Application for Filing FDA Assigns Priority Review and PDUFA Date of October 22, 2009 No Current Therapies Indicated to Improve Walking Ability in People with MS

HAWTHORNE, N.Y.--(BUSINESS WIRE)--May. 6, 2009-- Acorda Therapeutics, Inc. (Nasdaq: ACOR)

• » Read on

23.04.09

Acorda Therapeutics Resubmits New Drug Application for Fampridine-SR for Improvement of Walking Ability in People with Multiple Sclerosis

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Apr. 23, 2009-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the resubmission of its New Drug Application (NDA) for Fampridine-SR to the U.S. Food and Drug Administration (FDA). Fampridine-SR is a novel therapy being developed to improve walking ...

• » Read on

02.02.09

Acorda Therapeutics Submits New Drug Application for Fampridine-SR for Improvement of Walking Ability in People with Multiple Sclerosis

•  Acorda Submitted New Drug Application (NDA) for Fampridine-SR on January 30, 2009  
• No Current Therapies Indicated to Improve Walking Ability in People with MS

HAWTHORNE, N.Y.--(BUSINESS ...

• » Read on

08.01.09

Victory Pharma announces launch of additional Naprelan® prescription products

SAN DIEGO (January 8, 2009) –Victory Pharma, Inc., a privately held specialty pharmaceutical company, today announced that it is launching two additional dosage strengths of NAPRELAN® (naproxen sodium) Controlled-Release Tablets. NAPRELAN is a once-daily, controlled-release ...

• » Read on

19.12.08

AstraZeneca and MAP Pharmaceuticals Announce Worldwide Collaboration to Develop and Commercialize Unit Dose Budesonide

LONDON and MOUNTAIN VIEW, Calif., Dec 19, 2008 /PRNewswire-FirstCall via COMTEX News Network AstraZeneca (NYSE: AZN) and MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today an exclusive worldwide agreement to develop and commercialize Unit Dose Budesonide (UDB), MAP ...

• » Read on

13.11.08

FDA Approves 30-Minute Onset of Action for Focalin® XR

Data indicate Focalin XR provides rapid and significant improvements in attention, behavior and academic productivity at 30 minutes post-dose EAST HANOVER, N.J., November 12, 2008 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved a 30-minute onset of action for ...

• » Read on

10.11.08

Azur Pharma and Elan Corporation Sign Agreement to Develop a Once-Daily Clozapine

DUBLIN, Ireland -- November 10, 2008 -- Azur Pharma Limited (“Azur”) today announced that it has entered into an agreement to develop and commercialise once-daily formulations of clozapine using Elan Corporation plc’s (“Elan”)(NYSE:ELN) proprietary drug delivery ...

• » Read on

08.07.08

Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day

Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day Tuesday July 8, 8:00 am ET Focalin XR demonstrated better symptom control versus Concerta from 30 minutes to six hours post-dose in ...

• » Read on

04.06.08

Acorda Therapeutics Announces Positive Data from Second Phase 3 Study of Fampridine-SR on Walking Ability in People with Multiple Sclerosis

Company Plans to File New Drug Application (NDA) in First Quarter of 2009 Investor Conference Call and Webcast Today at 8:30 A.M. ET HAWTHORNE, N.Y.--(BUSINESS WIRE)--June 2, 2008--Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced positive results from ...

• » Read on

27.11.07

Zogenix Licenses Exclusive U.S. Commercial Rights for Late Stage, Controlled-Release, Opioid Product from Elan

SAN DIEGO, CA (November 27, 2007)   Zogenix, Inc. (”Zogenix”), a private, specialty pharmaceutical company, today announced they have entered into a License Agreement under which Zogenix has been granted exclusive US rights from an affiliate of Elan Corporation, plc (NYSE: ...

• » Read on

29.10.07

Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate

Titusville, NJ (October 29, 2007) – Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for paliperidone palmitate, an investigational, once-monthly ...

• » Read on

05.09.06

Additional NanoCrystal® Technology Patent Issued

Spring Valley, NY, Sept. 5, 2006 – Par Pharmaceutical Companies, Inc. (NYSE:PRX) today announced that a new patent has been issued by the U.S. Patent and Trademark Office (PTO) relating to Megace®  ES (megestrol acetate) 625 mg/5 mL oral suspension, which utilizes Elan’s ...

• » Read on